about
Genomic organization and promoter characterization of human CXCR4 geneNatural killer KIR3DS1 is closely associated with HCV viral clearance and sustained virological response in HIV/HCV patientsThe CXCL12gamma chemokine displays unprecedented structural and functional properties that make it a paradigm of chemoattractant proteinsDifferences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patientsHigh transcript levels of vitamin D receptor are correlated with higher mRNA expression of human beta defensins and IL-10 in mucosa of HIV-1-exposed seronegative individuals.IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in CaucasiansShort communication: atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis CCommon haplotypes in CD209 promoter and susceptibility to HIV-1 infection in intravenous drug users.Transforming growth factor-beta1 down-regulates expression of chemokine stromal cell-derived factor-1: functional consequences in cell migration and adhesion.IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection.Longitudinal evaluation of hepatitis C viral persistence in HIV-infected patients with spontaneous hepatitis C clearance.Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection.Evolutionary analysis identifies an MX2 haplotype associated with natural resistance to HIV-1 infection.Vitamin-D pathway genes and HIV-1 disease progression in injection drug users.Association of low-density lipoprotein receptor genotypes with hepatitis C viral load.Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection.Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection.A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers.Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype.A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients.Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.Differences in virological response to peginterferon-α plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b.LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients.Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV.Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype.Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients.Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4.Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy.Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients.Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse.Site-directed antibody immobilization using a protein A-gold binding domain fusion protein for enhanced SPR immunosensing.Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis.Developmental expression profile of the CXCL12gamma isoform: insights into its tissue-specific role.Vitamin D receptor gene haplotypes and susceptibility to HIV-1 infection in injection drug users.Estrogen receptor alpha gene variants are associated with Alzheimer's disease.High frequency of the 3'A mutation of the SDF-1 gene in Cambodia.Endoplasmic reticulum aminopeptidase 2 haplotypes play a role in modulating susceptibility to HIV infection.
P50
Q28271622-DE9DB64B-6DE7-4BF1-BEEC-A0466AEF6A39Q31115968-B123A05B-E491-46FC-B74D-CB82FF49B187Q33354115-64C0C737-0FD5-4748-8A6C-64B4AD5EFC87Q34473823-71AB5AE0-21F1-4861-8E6A-FC61E3EF6E16Q35070462-B9D585A3-AEB2-4EC9-9EA2-D67FFB99E8AEQ35153222-156929AB-562D-4203-B830-A2CC618AB6D3Q36553967-F14A97D9-C2A9-4D4E-B57C-7656C9951C4DQ40493714-922BC07F-826F-4AB8-A4C6-C090D9FDE2D5Q40643937-8A607BAF-25D6-4A76-B4EE-7EEDE76B5ADAQ40998744-3BEAB6F7-5F43-4A11-8B90-3533EE9D0449Q41063380-17E727C3-17C2-4D8C-B339-02F90263FC73Q41556124-87F21DA2-9992-4D8A-84D7-00549401DE48Q42210416-B2B9BCEE-AD22-4DFA-B7AE-422EE728DCBDQ42222162-F56396E5-F747-4827-AFAD-121DACAED283Q42242404-E549447E-B0BD-47FC-9085-14E2583F1D76Q42255661-FC0F0E4B-791F-4F9B-9A93-FD930287B67DQ42261289-769DDDB1-20D1-41A4-AD2B-C8E204A5D6BFQ42262070-E301E51D-ED61-411E-A000-98D8D7BC7C5CQ42268590-8461486A-0E5B-44C0-AAAF-1006B7A20347Q42278881-70FC085F-9A6C-4E28-A323-6C554DD7E527Q42282496-66216D52-465A-4581-89F1-8733C02685A9Q42922285-5688A9D2-52C2-4DE8-BB0F-3B5CF4873EC3Q42977958-D555117A-3D57-449D-9889-0723EBF6B138Q42978101-D3DE25B6-3A41-4CE8-8F85-8ADE7C750D01Q42985117-73A2E345-9132-469C-8A14-989BAA629960Q43000776-FC607603-9807-48EC-AE3D-C9DE57996EA0Q43034902-513369B7-F040-46DE-949C-AC1276B87A03Q43034985-5EAC2927-E4E5-4E40-B67F-5FFB894E3F52Q43041184-E9B76541-B331-4463-BAA4-D20258C75B1AQ43047573-45F0DC24-7816-427F-8E91-8297EC5C1715Q45366419-324A9A8E-FCD0-4688-ACF8-E78648D8AE33Q45366536-1673C6AF-7EC7-46B6-A4D9-0621D5C53F66Q45366889-87109B9E-1FEE-4861-A94B-284B00DD547AQ45384310-D8E6EB6E-1388-458D-B9DA-12481C6FB9F9Q45763095-4EFD241F-9E24-4D1C-94BA-874B7428DCE4Q46000895-62F9EDB4-C935-4181-8A60-6A9FD15D5738Q46800876-31389585-8CFA-420A-9583-D61C509AFDD0Q53311655-246BACD8-2D97-4837-BFB3-066E746EDC2EQ54013870-6065C819-B4D4-49D3-91A2-72F7FF4E42C1Q54270946-151FADBC-32D4-4EBE-A60C-D9461FFD1DBF
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Antonio Caruz
@ast
Antonio Caruz
@en
Antonio Caruz
@es
Antonio Caruz
@nl
type
label
Antonio Caruz
@ast
Antonio Caruz
@en
Antonio Caruz
@es
Antonio Caruz
@nl
prefLabel
Antonio Caruz
@ast
Antonio Caruz
@en
Antonio Caruz
@es
Antonio Caruz
@nl
P108
P1053
N-5557-2014
P106
P1153
6602444308
P21
P31
P3829
P3835
antonio-caruz
P496
0000-0002-5788-7840